The injectable Vi polysaccharide typhoid vaccine is cheap (50 US cents per dose) and potentially useful in developing countries. There have been questions, however, about programme feasibility, whether it is protective in young children (aged 2–5 years), and whether it is ableBMJ...
Typhoid: vaccine preventable diseases surveillance standards. WHO https://www.who.int/publications/m/item/vaccine-preventable-diseases-surveillance-standards-typhoid (2018). Basnyat, B., Qamar, F. N., Rupali, P., Ahmed, T. & Parry, C. M. Enteric fever. BMJ 372, n437 (2021). Article ...
Typhoid: vaccine preventable diseases surveillance standards. WHO https://www.who.int/publications/m/item/vaccine-preventable-diseases-surveillance-standards-typhoid (2018). Basnyat, B., Qamar, F. N., Rupali, P., Ahmed, T. & Parry, C. M. Enteric fever. BMJ 372, n437 (2021). Article ...
The vaccine-preventable burden of clinical typhoid presenting as hospitalization with prolonged fever of greater than 5 days. Justification: In most settings with high typhoid burden, the main concern – other than mortality – is likely to be severe disease and high cost health care utilization. ...
Bharat Biotech, which has rolled out a live attenuated oral rotavirus vaccine in India, announced results from a study using its Typbar TCV, a conjugated typhoid vaccine, in The Lancet. India is an Emerging Hub For Low-cost Vaccines: Improvising basic vaccines to enhance stability, efficacy and...
Data on the burden of disease, costs of illness, and cost-effectiveness of vaccines are needed to facilitate the use of available anti-typhoid vaccines in developing countries. This one-year prospective surveillance was carried out in an urban slum community in Delhi, India, to estimate the cost...
A forecast of typhoid conjugate vaccine introduction and demand in typhoid endemic low- and middle-income countries to support vaccine introduction policy and... V Mogasale,E Ramani,IY Park,... - 《Human Vaccines & Immunotherapeutics》 被引量: 1发表: 0年 Cost-effectiveness analysis of typhoid ...
In December 2017, the World Health Organization (WHO) prequalified the first typhoid conjugate vaccine (TCV; Typbar-TCV). While no safety concerns were identified in pre- and postlicensure studies, WHO's Global Advisory Committee on Vaccine Safety recommended robust safety evaluation with large-...
> Section > Chapter Papadimitropoulos, V.; Vergidis, P.I.; Bliziotis, I.; Falagas, M.E. Clinical Microbiology and Infection the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 10(8): 681-683 ...
We performed five additional scenario analyses that evaluated the cost-effectiveness of all delivery strategies under the assumption that the cost per dose would be I$2 or I$5 (based on the costs of other Gavi-supported vaccines) and the current price of the Typbar-TCV vaccine in India (180...